Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from first-line immunotherapy in NSCLC

Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from first-line immunotherapy in NSCLC

Abstract Background Many studies have compared real-world clinical outcomes of immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC) with reported outcomes data from pivotal trials. However, any differences observed could be only limitedly explored further for causation becaus...

Full description

Bibliographic Details
Main Authors: R. K. Ismail, F. M. N. H. Schramel, M. van Dartel, A. M. G. Pasmooij, C. M. Cramer-van der Welle, D. L. Hilarius, A. de Boer, M. W. J. M. Wouters, E. M. W. van de Garde
Format: Article
Language:English
Published: BMC 2023-01-01
Series:BMC Medical Research Methodology
Subjects:
NSCLC
Nivolumab
Real-world
Efficacy- effectiveness gap
Online Access:https://doi.org/10.1186/s12874-022-01760-0

Internet

https://doi.org/10.1186/s12874-022-01760-0

Similar Items